Introduction
Candida species are important pathogens causing healthcare-associated infections and are associated with high mortality, excess lengths of hospital stay, and medical costs.
1,2 A nation-wide surveillance data in Taiwan showed that Candida species was the leading pathogens of healthcare-associated infections in the intensive care units (ICUs) of the medical centers and ranked second in regional hospitals in 2010. 3 The incidence of bloodstream infections with fungi (especially Candida species) has increased substantially during recent decades. 4e7 The potential reasons include increase in patient population at risk, and more extensive use of invasive procedures and devices, broad-spectrum antimicrobial agents, advanced life-support, and aggressive chemotherapy. The incidence of candidemia varies between countries, patient populations, and study periods. 4e7 The incidence of candidemia in a multicenter study of healthcare-associated bloodstream infection in Taiwan varied widely between hospitals, and the highest incidence was observed in a cancer center. 7 In a hospital-wide surveillance study we observed an average of 15.0% increase annually in incidence of healthcare-associated bloodstream infection during 1981 and 2007, 6 and Candida species have become the leading healthcare-associated bloodstream pathogens since 1993. 8 A prospective observational study during 1994 and 1995 showed high incidences of candidemia in surgical and medical intensive care units and hemato-oncology units (9.4, 6.3 and 2.4 per 1000 discharges, respectively), and no antifungal therapy was an independent factor associated with mortality. 9 Since then, we adopted empirical antifungal therapy for high-risk patients using either amphotericin B or fluconazole. 10 In a recent study, we observed a significant increase of hospitalized patients with neoplasms from 22.0% during  January 1999 and March 2004 to 31.7% during April 2004 and  December 2007. 11 Therefore, we retrospectively analyzed the hospital-wide prospective surveillance data at this 2300-bed teaching hospital in Taiwan and aimed to describe and compare the patient population hospitalized in 2002 and 2010 and determine the disease-specific incidences of candidemia, as well as evaluate the impact of time to initiate antifungal therapy on 30-day mortality.
Patients and methods

Hospital setting and infection control surveillance program
National Taiwan University Hospital (NTUH) is a 2300-bed major teaching hospital in Taiwan that provides both primary and tertiary medical care. Prospective, hospitalwide on-site surveillance of Healthcare-associated infections (HCAIs) had begun since 1981, and it was conducted by weekly visits of full-time infection control nurses to all patient units. The clinical and microbiologic data of all hospitalized patients were reviewed, healthcareassociated infections were defined according to the definitions provided by the U.S. Centers for Disease Control and Prevention, 12, 13 and relevant information were collected. 6 There was no cluster of Candida colonization or infection documented during the study period. Besides, a previous active microbial surveillance study conducted during 1996-1997 when the incidence of invasive candidiasis increased rapidly at NTUH showed that Candida colonization was common in adult patients stayed in the intensive care units (ICUs). 14 In addition, molecular epidemiologic study based on pulse-field gel electrophoresis findings did not identify cross-transmission between these patients. 14 
Data collection or sources
All patients hospitalized at NTUH in 2002 and 2010 were analyzed for the distribution of age, sex, type of underlying diseases, and source of patients (from outpatient clinics, emergence services, or transfer from other hospitals). Underlying diseases, comprising a maximum of six diseases, were recorded and classified according to International Classification of Diseases, 9th Revision, Clinical Modification (ICD-9-CM) codes, which were coded by Medical Information Management personnel when patients were discharged from the hospital.
All patients with blood isolates which were collected in 2002 and 2010 and yielded Candida spp. were included for analysis of the demographic and clinical characteristics, distribution of Candida species, length of hospital stay before and after onset of candidemia, ICU stay at the onset of candidemia, use of antifungal agent, time of initiating systemic antifungal agent, antifungal regimen, and 30-day crude mortality and in-hospital mortality. We did not record the therapeutic factors other than antimicrobial agents (such as parenteral nutrition, indwelling central lines) and delayed complications after discharge due to candidemia. The laboratory methods for blood culture, Candida spp. identification and antimicrobial susceptibility were described previously. 15, 16 Antifungal strategy We adopted empirical antifungal therapy for high-risk patients using either amphotericin B or fluconazole 13 as a series of studies showed clinical isolates of Candida spp. collected at NTUH remained highly susceptible to fluconazole and amphotericin B. 10, 17, 18 Besides, Golan et al demonstrated that empirical fluconazole therapy was the most cost-effective strategy for ICU patients with high risks for candidemia if fluconazole resistance rate was low. 19 Antifungal prophylaxis was limited to allogeneic hematopoietic stem cell transplant recipients using fluconazole 19 or micafungin (since 2008).
Definitions
The severity of underlying diseases, comprising a maximum of six diseases, was scored using the Charlson Comorbidity Index. 20 Candida colonization was defined as any Candida isolated from any decision-driven clinical specimens collected from the patients in the preceding 1 month of candidemia. The timing to initiate antifungal therapy was determined as the date to initiate antifungal agents following the date when the first Candida-positive blood sample for culture was drawn (Day 0). We segregated these times as being on the same calendar day, 1 day later, 2 days later, 3 days or more days later. No treatment was defined as no systemic antifungal agents used during hospitalization after the onset of candidemia. Breakthrough candidemia indicated the patients had been on systemic antifungal agents at the time when the first Candida-positive blood sample for culture was drawn.
Statistical analysis
The difference in patient population and patients with candidemia during the two study periods was examined using Student's t-test (continuous variables) and a chisquared test (categorical variables). The incidences of 6 As regards to the risk factors of candidemia, the univariate analyses were undertaken using logistic regression. All variables significant at p < 0.05 in univariate analyses were considered as possible predictor variables for the multivariable analyses, which was performed by stepwise logistic regression. However, Charlson Comorbitidy Index were not included in multivariate analyses model because of colinearity with underlying diseases. All statistical tests were considered two-tailed and were significant at p <0.05. Statistical analyses were performed using SAS 9.2 (SAS Institute, Cary, NC, USA).
Ethics statement
We followed the principles expressed in the Declaration of Helsinki. This study was approved by the Institutional Ethics Review Board of the National Taiwan University Hospital (NTUH-201204058RIC).
Results
Patient population
The characteristics of patients hospitalized in 2002 and 2010 are summarized in Table 1 
Candida species distribution
There were 218 and 286 patients who had candidemia during hospitalization in 2002 and 2010, respectively. The distributions of Candida species were similar in these two study periods (p Z 0.26). The most common species were C. albicans (55.0% in 2002 vs. 53.2% in 2010), followed by C. tropicalis (20.2% vs. 23.1%), C. glabrata (15.6% vs. 18.5%), and C. parapsilosis (14.2% vs. 9.1%).
Risk factors of candidemia
The risk factors of candidemia among patients hospitalized in 2010 are shown in Table 2 . By univariate analysis, odds ratios were higher in patients with extreme of age and higher Charlson Comorbidity Index. Multivariate logistic 
Characteristics of patients with candidemia
The demographic and clinical characteristics of the patients with candidemia are shown in Table 3 Fig. 2A and Fig. 2B . There was no difference between these two study years. The disease-specific incidences of patients with candidemia increased among patients with moderateto-severe renal diseases (p Z 0.01), but decreased among those with gastrointestinal malignancy (p < 0.001), and metastatic malignancy (p Z 0.01) in 2010 (Table 3) .
Antifungal therapy and outcomes evaluation
As shown in Table 4 
Discussion
This hospital-based population study demonstrated that the incidence density of candidemia increased in 2010 comparing to that in 2002. The reason for this trend, at least in part, was due to the increase in the proportion of patients at higher risk of candidemia (Table 1 , Fig. 1 ) including older patients, and patients with chronic pulmonary diseases, leukemia, lymphoma, gastrointestinal malignancies, and metastatic solid tumors (Table 2) . However, the majority of age group-specific and diseasespecific incidences of candidemia did not change significantly (Table 3, Fig. 2 ). Although more patients in 2010 were treated earlier (Table 4) , the 30-day mortality rate remained high and time to initiating antifungal therapy had no impact on 30-day mortality.
In this study we showed the incidence density of candidemia up to 0.34 to 0.41 per 1,000 patient-days in 2002 and 2010, respectively, were higher than those in the United States, Europe, and Australia, 5,21e26 and were comparative to those in Latin America 27, 28 and a recent study in a medical center in Taiwan. 29 A multicenter study involving 11 teaching hospitals in Taiwan also showed relatively high incidences of healthcare-associated candidemia compared with those worldwide. 10 However, few if any study providing data to explain this variation between hospitals/countries/regions or time trends. In 2010 more than one-third of our patient populations had one or more neoplasms. Thus, composition of patient populations should be taken into consideration when comparing disease burden between hospitals or study periods.
Few population level studies provided age group-specific or underlying disease/status-specific incidences of candidemia.
30e33 With these data available, it is possible that the disease burden can be adjusted and compared between hospitals and study periods. In addition, we could predict The high-risk patient population for of candidemia included neonate, the elderly, patients with moderate-tosevere renal diseases, gastrointestinal malignancies, or hematologic malignancies. These findings are consistent with those described in review articles. 34e36 In this study there was no candidemia occurring among hematopoietic stem cell transplantation recipients, which support the success of antifungal prophylaxis before engraftment.
In this study we observed an unanticipated finding that timing of initiating antifungal agent had no impact on 30-day mortality. This finding was concordant to two recent reports 37, 38 but differed from others. 39, 40 As to this discrepancy, severity of illness, such as the Acute Physiology and Chronic Health Evaluation (APACHE) II score, should be taken into consideration. APACHE II score has been a well-known independent predictor of mortality, which might confound the impact of earlier initiating antifungal therapy on mortality. 41 Furthermore, more patients in 2010 received antifungal therapy on one day later, which might reflect the effect of continuous education for our physicians to identify patients at risk and implement empirical strategy. In addition, the outcome was worse among patients without antifungal therapy in 2010 than those in 2002, probably because the majority of them died before confirmation of the diagnosis.
Although this population study provides robust information from epidemiological perspectives, there are several limitations. First, this study did not provide information regarding invasive procedure to adjust the disease-specific incidence. Second, the lack of APACHE II score in this study might lead to more prudent interpretation of the impact of timing of initiating antifungal therapy on mortality. Third, the underlying diseases were retrieved from ICD-9 CM codes of discharge diagnosis and limited to six. Thus, diseasespecific incidences might be underestimated or overestimated. Furthermore, this is a single-center study with study periods limited to 2002 and 2010.
In conclusion, this hospital-based population study demonstrated that the incidence density (and incidence) of candidemia was high and increased in 2010 compared with 2002, which, at least in part, was due to the increase in the proportion of patients at higher risk of candidemia. The 30-day mortality remained high in 2010, which is even earlier initiation of antifungal therapy.
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